The global aerosol delivery devices market is foreseen to expand at a CAGR of 4.9% and reach the valuation of USD 46.72bn in 2027 in comparison to USD 31.46bn in 2019.
Aerosol drug devices can treat a host of diseases such as lung diseases, pneumonia, diabetes, asthma, etc. which further drives the global aerosol delivery devices market during the forecast years.
Researchmoz elucidates the market in detail including market size, opportunities, restraints, drivers, and segment domination.
Chronic obstructive pulmonary disease (COPD) to Drive the Market
Chronic obstructive pulmonary disease (COPD) is the most common death-causing disease in the world and drug delivery via inhalation process is the common treatment for COPD. The disease affects nearly 15% of the US population, thus, the increasing prevalence of COPD is projected to drive the global aerosol delivery devices market.
The drug delivery system has had a transformational shift since its inception, from just metered-dose inhalers to handheld inhalers such as dry powder and soft mist inhalers. The growing patient population and growing need for targeted therapies have encouraged a better understanding of the applications of aerosol drug delivery.
Self-administration to Boost the Sales of Aerosol Delivery Devices
The pharmaceutical industry is highly focused on patient-centricity through bringing in self-administration and giving ease and real-time experiences to the patients, owing to the expansion of the global aerosol delivery devices market.
According to pharma experts, innovations in the field of drug delivery will make manufacturers and pharma companies, researchers, and scientists to work together and introduce digitization, leading to the expansion of the global aerosol delivery devices market.
The high cost of treatment and side effects of medication might hinder the growth of the global aerosol delivery devices market to some extent.
However, the rising geriatric population with severe respiratory diseases such as asthma, COPD, etc. will drive the global aerosol delivery devices market.
Non-respiratory diseases such as diabetes, thyroid, Parkinson’s disease, and some genetic disorders will also drive the global aerosol drug delivery market during the forecast years.
The dry powder inhalers segment will be the aerosol delivery device market over the forecast period due to its efficacy and design.
The common line of treatment is inhalation therapy in diseases such as asthma, which would encourage growth opportunities in the global aerosol delivery devices market in the coming years.
Asia Pacific will hold a larger share in the global aerosol delivery devices market, owing to the prevalence of diseases like asthma, COPD, Pneumonia, etc.
Reasearchmoz puts forth a comprehensive report about the competitive landscape of the aerosol delivery devices market. The report includes all the aspects of the market including the strategies that key companies are focusing on in order to thrive in the global market and tap into untouched areas.
Some of the prominent players in the global aerosol drug delivery market are-
- Koninklijke Philips N.V.
- 3M Company
- Aerogen, INC
- GlaxoSmithKline Plc (GSK)
- Merck & co., INC.
- Metall Zug Group (Clement Clarke International Ltd)
- Merxin LTD
- Iconovo AB
- Gerresheimer AG
- Recipharm AB (Bespak)
- Johnson & Johnson (Actelion Pharmaceuticals Ltd)
- Teva Pharmaceutical Industries Limited
- Vectura Group PLC
Some of the key takeaways from the detailed report shared by Researchmoz are as follows-
The global aerosol delivery devices market is expected to exhibit substantial growth at a CAGR of 4.9%.
Chronic obstructive pulmonary disease (COPD) will drive the market largely as it is a common respiratory disease.
Patient-centric approaches by pharmaceutical companies will strengthen the aerosol delivery devices market.
Asia Pacific will dominate the regional segment of the global aerosol delivery devices market due to growing COPD, asthma, and other respiratory diseases among patients.
- Dry powder inhalers
- Single-dose inhalers
- Multi-dose inhalers
- Reservoir Inhalers
- Metered-dose inhalers
- Conventional pressurized inhalers,
- Soft mist inhalers
- Jet nebulizers
- Ultrasonic wave nebulizers
- Vibrating mesh nebulizers
- Chronic obstructive pulmonary disease
- Cystic fibrosis
- Parkinson’s disease